Leukapheresis Products Market Research Report Information By Type (Leukapheresis Devices, Leukapheresis Disposables), Application (Research Applications, Therapeutic Applications), End User (Blood Component Provider and Blood Center, Other) -Forecast Till 2032

Leukapheresis Products Market Overview

Leukapheresis products market is expected to reach USD 27.1 million at a CAGR 7.8% during the forecast period 2023-2032. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs). Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia. Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.

Segmentation:

The leukapheresis products market has been segmented into type, application, and end user. On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.

The market, on the basis of application, has been segmented into research applications and therapeutic applications.

On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others are some of the key players in the  leukapheresis products market.

Regional Market Summary: Global Leukapheresis Products Market Share (%), by Region, 2017

Source: America’s Blood Centers, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.

Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.

The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.

The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Recent Development

Cryoport Inc. and Cell Matters SA formed a strategic agreement in February 2022 to provide end-to-end cryopreservation services for leukapheresis-derived therapies in the life sciences industry, enabling both autologous and allogeneic cell therapies. Terumo Blood and Cell Technologies revealed in July 2021 that physicians would be able to perform extracorporeal photopheresis immunotherapy (ECP) operations at the patient's bedside. Spectra Optia's functionality has been enhanced by the firm. These devices can now be used to perform the UVA PIT System ECP as a functionally closed, online, multistep system using mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.

Leukapheresis Products Market, by Type

• Leukapheresis Devices


• Apheresis Devices


• Leukapheresis Columns & Cell Separators


• Leukoreduction Filters

• Leukapheresis Disposables

Leukapheresis Products Market, by Application

• Research Applications


• Therapeutic Applications

Leukapheresis Products Market, by End User

• Blood Component Providers and Blood Centers


• Hospitals and Transfusion Centers


• Others

Leukapheresis Products Market, by Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • South America
  
  
  
  


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• The Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Leukapheresis Products Market, by Key Players

• Haemonetics


• Terumo BCT


• Asahi Kasei Medical


• STEMCELL Technologies


• Macopharma


• Caltag Medsystem


• ZENBIO


• Fresenius Kabi


• PPA Research Group


• StemExpress


• HemaCare Corporation


• ALLCells, LLC


• Others

Intended Audience

• Apheresis Device Manufacturers and Distributors


• Leukapheresis Product Manufacturers and Distributors


• Pharmaceutical and Biotechnological Companies


• Healthcare Service Providers (including Hospitals and Transfusion Centers)


• Cancer Treatment Centers


• Blood Component Providers & Blood Centers


• Contract Research Organizations


• Academic and Research Institutes


• Government Associations

Report Attribute/Metric	Details
Market Size	USD 27.1 Million
CAGR	7.8% (2023-2032)
Base Year	2019
Forecast Period	2023-2032
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Application and End user
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	·  Growing number of blood donations Increasing prevalence of leukaemia ·  Demand for leukapheresis products in clinical researc